Propanc Biopharma files patent for PRP‑galunisertib pancreatic cancer combination and readies Phase 1b trial
Propanc Biopharma announced preclinical data showing its pancreatic proenzyme formulation PRP cuts cell proliferation and invasion in both wild‑type and gemcitabine‑resistant pancreatic cancer models, with greater effects when combined with the TGF‑β inhibitor galunisertib. The company filed an Australian patent application covering the PRP‑galunisertib combination and said it is preparing a Phase 1b first‑in‑human study of the combination, now named PPC‑001. CEO James Nathanielsz highlighted the approach as a new way to overcome resistance mechanisms in pancreatic ductal adenocarcinoma.
Why it matters
The company’s filing secures intellectual‑property protection for the combination, potentially enhancing its commercial value if clinical trials succeed. Investors should watch for upcoming Phase 1b trial initiation, which could affect future financing needs and valuation.
Key facts
- 1PRP reduced cell proliferation by approximately 50% in both wild‑type and gemcitabine‑resistant pancreatic cancer cells. investing.com
- 2The PRP‑galunisertib combination reduced proliferation by 75% in wild‑type cells and 66% in resistant cells. investing.com
- 3PRP lowered colony formation by 59% (wild‑type) and 39% (resistant); the combination lowered it by 68% and 64% respectively. investing.com
- 4In invasion assays, PRP cut invasion by 81% (wild‑type) and 47% (resistant); the combination cut it by 89% and 80% respectively. investing.com
- 5The company filed an Australian patent application for the PRP‑galunisertib combination. investing.com
- 6Propanc is preparing a Phase 1b first‑in‑human study of the combination, now called PPC‑001. rttnews.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.